To evaluate the Safety and efficacy of Unani formulations in Productive Cough

Validation of Unani Pharmacopoeial formulation- Sharbat ZÅ«fÄ? Murakkab in patients of SuÄ?l Ratab (Productive Cough)

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2013/11/004171

Enrollment

540

Registered

2013-11-25

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: R05- Cough Health Condition 2: null- SuÄ?l Ratab (Productive Cough).

Interventions

Intervention1: Sharbat ZÅ«fÄ? Murakkab: 10 ml three times daily with lukewarm water for two weeks Control Intervention1: NIL: NIL

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients of either sex in the age group of 18-65 2. Complaint of Cough with a H/O of > 3 days duration 3. Associated with expectoration

Exclusion criteria

Exclusion criteria: 1. Cases of non-productive cough 2. Known cases of respiratory diseases needed concomitant therapy e.g. Pneumonia, Bronchiectasis, Bronchial Asthma, Pulmonary Tuberculosis and Lung Carcinoma. 3. Known cases of Renal/ Hepatic/ Cardiac impairment or the ailments needing long term therapy 4. Pregnant or lactating women

Design outcomes

Primary

Measure	Time frame
Improvement in signs and symptoms of SuÄ?l Ratab (Productive Cough).Timepoint: 2WEEKS	—

Secondary

Measure	Time frame
Haematological and biochemical assessment for safety assessmentTimepoint: 2 WEEKS	—

Countries

India

Contacts

Public ContactDR ABDUL HANNAN

Central Council for Research in Unani Medicine (CCRUM),

ccrum605@gmail.com01128521981

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026